Study wrapper · #239
An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.
Editor's note
This is an analytical-chemistry paper, not a study of what CJC-1295 does in the body. Researchers built an immuno-PCR assay able to detect the CJC-1295–albumin conjugate down to sub-picogram levels in horse plasma, then confirmed it in thoroughbreds given the peptide. Read it as anti-doping method development: it tells us CJC-1295's defining feature — the maleimidopropionic acid group that covalently tethers it to plasma proteins and stretches its half-life to days — is precisely what defeats conventional mass-spectrometry screens, forcing a purpose-built antibody assay. It says nothing about efficacy, safety, or human physiology. For readers, the useful takeaway is contextual: CJC-1295's long action reflects irreversible albumin binding, and detection science has had to adapt to it. Weight this as forensic/regulatory infrastructure, not clinical evidence. The human pharmacology of CJC-1295 rests on a separate, small body of Phase II data.
Plain-language abstract
This paper describes a laboratory test, not a health study. CJC-1295 is a 30-amino-acid peptide that prompts the pituitary gland to release growth hormone. Unusually, it carries a reactive chemical group that permanently latches onto proteins in the blood, which keeps it active far longer than most peptides and effectively hides it from the standard mass-spectrometry methods used in drug testing. To catch it, the researchers developed a highly sensitive test (immuno-polymerase chain reaction, or I-PCR) using two antibodies made against CJC-1295. The test could detect the peptide-protein complex at concentrations as low as 0.8 picograms per millilitre. Because horses naturally produce a related hormone, the practical cut-off for calling a sample positive was set at 50 pg/mL. The method worked on real blood samples from racehorses that had been given the drug. The study was designed purely to help control illicit use in equine sport; it does not examine whether CJC-1295 is effective or safe in humans or animals.